CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity

Hidekazu Shirota, Dennis M. Klinman

研究成果: Article査読

33 被引用数 (Scopus)


The primary goal of cancer immunotherapy is to elicit an immune response capable of eradicating established tumors and preventing tumor metastasis. One strategy to achieve this goal utilizes whole killed tumor cells as the primary immunogen. Killed tumor cells provide a comprehensive source of tumor-associated antigens (TAAs), thereby eliminating the need to identify individual antigens. Unfortunately, killed tumor cells tend to be poorly immunogenic. To overcome this limitation, we covalently conjugated immunostimulatory CpG oligodeoxynucleotides (ODN) to apoptotic tumor cells and examined their ability to induce TAA-specific immune responses. Results indicate that CpG conjugation enhances the uptake of cell-based vaccines by dendritic cells (DCs), up-regulates co-stimulatory molecule expression, and promotes the production of immunostimulatory cytokines. Vaccination with CpG-conjugated tumor cells triggers the expansion of tumor-specific cytotoxic T lymphocytes (CTL) that reduce the growth of established tumors and prevents their metastatic spread. Thus, conjugating CpG ODN to cell-based tumor vaccines is an important step toward improving cancer immunotherapy.

ジャーナルCancer Immunology, Immunotherapy
出版ステータスPublished - 2011 5

ASJC Scopus subject areas

  • 免疫アレルギー学
  • 免疫学
  • 腫瘍学
  • 癌研究


「CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。